Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Wolfgang Miesbach: A Remarkable Progress With Non-Factor Therapies in Hemophilia Care
Wolfgang Miesbach, Maria Elisa Mancuso/LinkedIn
Mar 26, 2026, 15:19

Wolfgang Miesbach: A Remarkable Progress With Non-Factor Therapies in Hemophilia Care

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

”Non-factor therapies in haemophilia – a paradigm shift for haemophilia treatment!

Excellent presentation by Maria Elisa Mancuso at EAHAD 2026 in Dublin, covering the remarkable progress with non-factor therapies (NFTs) – and important questions still ahead.

Emicizumab, fitusiran, concizumab, marstacimab, and the emerging FVIIIa mimetics (MIM8/denecimig, NXT007) enable effective prophylaxis across a broad patient spectrum – including those with inhibitors and children with haemophilia A – with dramatically reduced treatment burden:

  • Emicizumab: mean ABR 0.2–1.4 across clinical trials and real-world data (66.7% zero bleeds across all studies)
  • Fitusiran (ATLAS programme): mean ABR 1.7 in inhibitor patients, 3.1 in non-inhibitor patients
  • Concizumab: 86% reduction in ABR in HA without inhibitors vs. no prophylaxis; 79% reduction in HB
  • MIM8/denecimig: mean ABR 1.54 (QM) at 52 weeks
  • Marstacimab: 87% reduction in ABR vs. on-demand in inhibitor patients

Remaining challenges and unknowns:

  • Long-term impact on joint health remains unknown
  • FVIIIa mimetics have lower affinity to FIX/FX than FVIII – FVIII-equivalence is hard to establish and animal models have proven unreliable
  • Absence of routine lab assays to measure precise hemostatic activity
  • Quality of haemostasis: fibrin clot structure under emicizumab or MIM8 differs from normal (as shown elegantly by scanning electron microscopy – Rezigue et al., Thromb Res 2025)
  • Thrombotic risk: 5 thrombotic/TMA events with emicizumab plus high-dose aPCC (HAVEN 1); thrombotic events also reported for concizumab, fitusiran (mitigated by AT-based dosing), and marstacimab.”

Wolfgang Miesbach: A Remarkable Progress With Non-Factor Therapies in Hemophilia Care

Stay updated with Hemostasis Today.

bleeding disorders Concizumab Denecimig EAHAD 2026 Emicizumab Fitusiran Headlines Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Maria Elisa Mancuso Marstacimab Medicine Mim8 NFTs Wolfgang Miesbach
NewsFeed